NV-387 / NanoViricides - LARVOL DELTA

NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo (Le Lézard) - "We have now completed submission of substantial required documentation in the draft forms as requested. We are now in the process of compiling all of this documentation together into the final form Clinical Trial Application, along with associated certifications and disclosures."

New P2 trial • Infectious Disease

A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials (ACCESS Newswire) - "NanoViricides...reports that its broad-spectrum antiviral drug NV-387 could help reduce resurgence of metastatic cancer caused by awakening of 'sleeping' cancer cells due to viral infections. NV-387 has successfully completed a Phase I clinical trial and is being advanced into Phase II clinical trials."

Clinical • Trial status • Oncology